Autoimmune cytopenias in chronic lymphocytic leukemia

Carlo Visco(University of Verona), Francesco Rodeghiero(Ospedale San Bortolo), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonino Neri(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Francesco Maura(Memorial Sloan Kettering Cancer Center)

American Journal of Hematology

June 10, 2014

10.1002/ajh.23785

Cited by 119

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

|Blood|2008|2.6k

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

|Leukemia|2009|877

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

|Cell|2018|565